Filing Details

Accession Number:
0000899243-18-027475
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-10-25 18:24:35
Reporting Period:
2018-10-23
Accepted Time:
2018-10-25 18:24:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1664106 Logicbio Therapeutics Inc. LOGC Biological Products, (No Disgnostic Substances) (2836) 471514975
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1706399 Erez Chimovits C/O Logicbio Therapeutics, Inc.
610 Main Street, 3Rd Floor
Cambridge MA 02139
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-10-23 2,997,760 $0.00 2,997,760 No 4 C Indirect See Footnote
Common Stock Acquisiton 2018-10-23 490,000 $10.00 3,487,760 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Convertible Preferred Stock Disposition 2018-10-23 2,678,571 $0.00 1,402,444 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2018-10-23 3,046,943 $0.00 1,595,316 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The total represents shares received upon conversion of Series A and Series B Convertible Preferred Stock.
  2. Upon closing of the Issuer's initial public offering, each share of Series A and Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series A or Series B Convertible Preferred Stock.
  3. The Reporting Person is an employee of OrbiMed Advisors Israel II Limited ("OrbiMed Limited"), which is the managing member of OrbiMed Israel GP II, L.P. ("OIP GP"). OIP GP is the general partner of OrbiMed Israel Partners II, L.P. ("OIP II"), the direct beneficial owner of these securities. By virtue of such relationships, OIP GP and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of these securities in which the Reporting Person has no pecuniary interest.